BiotechTube
SCHOTT Pharma

SCHOTT Pharma

1SXP.DE
Germany

SCHOTT Pharma leverages over 100 years of expertise to provide scientifically proven, holistic solutions for the pharmaceutical and biotech industries, from single components to complete drug delivery systems. Its portfolio, built on Type I Borosilicate Glass and high-grade polymers, is complemented by comprehensive services in analytics, regulatory support, and manufacturing optimization. As a publicly traded company, it sets industry standards for quality and innovation, focusing on ensuring compatibility and safety from clinical trials through commercial drug administration to patients worldwide.

schott-pharma.com

1SXP.DE · Stock Price

EUR 13.50-10.52 (-43.80%)
Market Cap: $2.4B

Historical price data

AI Company Overview

SCHOTT Pharma leverages over 100 years of expertise to provide scientifically proven, holistic solutions for the pharmaceutical and biotech industries, from single components to complete drug delivery systems. Its portfolio, built on Type I Borosilicate Glass and high-grade polymers, is complemented by comprehensive services in analytics, regulatory support, and manufacturing optimization. As a publicly traded company, it sets industry standards for quality and innovation, focusing on ensuring compatibility and safety from clinical trials through commercial drug administration to patients worldwide.

Broad Spectrum Injectable DrugsVaccinesBiologicsDiabetesObesityAesthetic Treatments

Technology Platform

SCHOTT Pharma's core technology platform is based on advanced materials science, specializing in Type I Borosilicate Glass and high-grade pharmaceutical polymers to create drug containment systems (syringes, cartridges, vials, ampoules). This is integrated with a comprehensive service platform for analytics, regulatory support, and fill-and-finish optimization.

Funding History

1
Total raised:$935M
IPO$935M

Opportunities

Growth is driven by the expansion of biologic drugs requiring specialized containment, the trend towards self-administration for chronic diseases, and increasing regulatory demands for comprehensive analytical and regulatory support.
Expanding polymer-based product lines and services for high-value segments like cell and gene therapy present significant opportunities.

Risk Factors

Key risks include dependence on a concentrated customer base, vulnerability to fluctuations in energy and raw material costs, intense competition from global peers, and the constant need to maintain stringent regulatory compliance across all manufacturing sites.

Competitive Landscape

Main competitors include Gerresheimer, Stevanato Group, Corning, and West Pharmaceutical Services. SCHOTT Pharma differentiates itself through its deep heritage in glass science, a fully integrated service model from analytics to regulatory filing, and a strong focus on innovation for next-generation therapies like mRNA and high-concentration biologics.

More companies in Germany →